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Abstract   There has been an increasing interest in applying biotechnology in formulating 
and characterising new and innovative drug delivery methods, e.g., drug-loaded 
biodegradable microneedles within the area of transdermal delivery technology. Recently, 
microneedles have been proposed for use in pain management, e.g., post-operative pain 
management through delivery of a local anaesthetic, namely, lidocaine. Lidocaine is a fairly 
common, marketed prescription-based local anaesthetic pharmaceutical, applied for 
relieving localised pain and lidocaine-loaded microneedles have been explored. The purpose 
of this review is to evaluate the properties of biodegradable polymers that may allow the 
preparation of microneedle systems, methods of preparing them and pharmacokinetic 
conditions in considering the potential use of lidocaine for delivery through the skin. 
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Introduction 
There has been an increasing interest in applying biotechnology in formulating new and 
innovative drug delivery methods, including biodegradable microneedles within the area of 
transdermal drug delivery technology (Orive et al. 2003; Olatunji and Das 2010; Olatunji and 
Das 2011). Conventional hypodermic needle delivery causes pain and anxiety, and requires 
medical personnel for administration. In contrast, the biodegradable microneedle, a drug-
loaded vehicle moulded into an all-in-one drug formulated micro-structure constructed from 
either biopolymer or sugar excipients, can be used to deliver drug almost painlessly to 
humans (e.g., Donnelly et al. 2010; Lhernould and Delchambre 2011; Olatunji and Das 2011; 
Gittard et al. 2012). These microneedles are economical due to fairly cheap materials, 
reproducible and are generally safe if microneedle fragments break off after piercing the skin 
surface as compared to other microneedles made with glass or metal. 
Large molecular weight proteins such as bovine serum albumin (BSA), growth hormones 
and vaccines have been successfully loaded into biodegradable microneedles (Lee et al. 
2008; Lee et al. 2011a; Raphael et al. 2010). Recently, the microneedles have also been 
explored for use in post-operative pain management through delivery of a local anaesthetic, 
lidocaine. Lidocaine provides short duration, superficial anaesthesia, to the pain-affected 
area (Kissin 2012). Lidocaine (Fig. 1a) comprises of a polar tertiary amine and a 
hydrophobic aromatic group on the opposite ends of the acetamide bond (Costa et al. 2008). 
It is hydrophobic as the basic drug but it is soluble in water as the ionised form of lidocaine 
hydrochloride (Fig. 1b) in which the tertiary amine is protonated (Ullah et al. 2012; Rajabi et 
al. 2011; Shaikh et al. 2011). Therefore, lidocaine can be encapsulated or dispersed in a 
drug delivery vehicle which could be either hydrophobic or hydrophilic.  
 
 
 
 
Fig. 1 a 
Fig. 1 b 
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In the present context, a vehicle for drug delivery is taken as a support material for 
formulating drugs usually in liquid-based or a semi-solid form to remain on the skin surface 
and facilitate the conditions necessary for transdermal drug delivery (Allen et al. 2005; Djabri 
et al. 2012; Subedi et al. 2010). An ideal drug carrier system or vehicle is sought for 
identifying optimal conditions in controlled release and transdermal permeation kinetics of 
the drug lidocaine. The main objective of using a vehicle is either to allow for fast initial 
release or permeation in skin with consideration to the suitability of suturing a superficial cut 
or a slow initial release and longer  steady state conditions lasting several hours with an 
alternative consideration to suturing and treating multiple lacerations at the localised area. 
A formulation of lidocaine has been developed by Fiala et al. (2011) for EMLA (eutectic 
mixture of local anaesthetics) containing lidocaine and prilocaine in hydrofluoroalkane as a 
propellant enhancer spray. Kaewprapan et al. (2012) studied lidocaine-loaded nanoparticles 
of dextran decanoate esters with varying degrees of substitution for suspension in aqueous 
medium. Petrisor et al. (2012) mixed lidocaine with silicone elastomer and analysed the 
controlled release effects of modifiers such as poly(vinylpyrrodidone), PVP, and poly(vinyl 
alcohol), PVA. Compared with injectable and skin- surface drug applicants, microneedles are 
highly beneficial in terms of constant needle lengths being below the length causing 
epidermal pain stimulation during insertion (Banga 2009), while respectively described as 
minimally invasive in forming micro-spaces (Daugimont et al. 2010) in conjunction to 
enhancing the movement of the active compounds through the skin (Ameri et al. 2010; Chu 
et al. 2010). 
Besides the laboratory-based studies mentioned above, there are a number of proprietary 
transdermal delivery systems for lidocaine. These include proprietary medicines in solution, 
semi-solid and patch delivery system. For example, lidocaine in solution is combined with a 
bacterially-derived hyaluronic acid gel formula to minimise the discomfort of injection as a 
tissue filler in the cosmetics industry (Monhiet et al. 2009). The proprietary name of the 
formulation is Prevelle Silk (Mentor Pharmaceuticals, www.mentorcorp.com). Lidocaine 
solution is marketed under the proprietary name of Xylocaine and is also available in an 
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injectable format (www.astrazeneca.co.uk). Clinical research has shown that a 1% (w/v) 
lidocaine subcutaneously injected once into the location of a lacerated, injured or tumour-
affected hand allows for successful local anaesthesia followed by surgical treatment (Tzeng 
and Chen, 2012). A lidocaine patch for the application to skin is also marketed with the 
proprietary name Lidoderm (www.Lidoderm.com). A Lidoderm (5% w/v) patch has been 
applied for the treatment of postherpetic neuralgia (Katz et al. 2002) and in the reduction of 
pain during treatment of Dercum’s disease (Desai et al. 2008). 
Conceptually, microneedle technology provides an attractive method for delivering 
lidocaine. For example, it may be possible to apply the drug over a large surface area on the 
body with no or little pain in contrast to traditional hypodermic injections. With microneedles 
it may be possible to control the drug delivery rate as well besides reducing wastage of the 
drug. As far as we know, there is no commercially-based lidocaine microneedle product 
available from pharmacies. However, there seems to be some developmental research for 
lidocaine microneedles. Recently, the 3M group developed a lidocaine solution mixed with 
Dextran to uniformly coat medical-grade, liquid crystalline polymer (class VI) for pre-clinical 
in vivo studies using biopsy porcine skin of live pigs resulting in successful delivery of 
lidocaine at a faster time compared to eutectic mixture of local anaesthetics (EMLA) 
composed of lidocaine and prilocaine as a combined eutectic formulation (Zhang et al. 2012; 
Schreiber et al. 2013). A less recent but highly significant development was made by 
Theraject, Inc (Kwon. 2004) with regards to determining the permeation flux of lidocaine 
through the skin by testing a Theraject MAT dissolvable microneedle system. This vehicle 
comprised sodium carboxymethyl cellulose mixed with lidocaine and was cast, compressed 
and moulded to dryness with a subsequent diffusion characterisation that confirmed the 
permeation flux had increased up to 12-fold compared to 10% (w/v) lidocaine as control 
(Kwon 2004). The degree of subsitition, in terms of exchanged hydroxyl groups to 
carboxymethyl groups in sodium carboxymethyl cellulose, effected solubility, viscosity, gel 
strength and electro-analytical behaviour as an anionic polymer in solution requires further 
work in order to aim for a plastic material property (Kundu et al. 2011). 
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While the above studies show the potential for applying the principles of biotechnology for 
preparing lidocaine-loaded microneedles, there is a clear need to make further progress on 
the methods of preparation and characterisation of the microneedles for drug delivery. It may 
also be necessary to learn from what have been done elsewhere while loading and 
delivering other molecules (e.g., insulin) using biodegradable microneedles. To address 
these issues, this review paper aims to evaluate critically the current developments in 
biodegradable microneedle systems for possible applicability in transdermal lidocaine 
delivery. In particular, this paper reviews the methods of preparation and the properties of 
biodegradable polymers that may allow for the development of a desirable microneedle 
system for lidocaine delivery. It is expected this would be helpful in preparing biodegradable 
microneedle for lidocaine delivery. 
 
Preparation of biodegradable microneedles 
The first published paper on microneedles was in 1947 in which soft glass material (30 
microns tip diameter and 2.5 cm long) was an example of early microneedles in assisting the 
isolation of yeast ascospores (Thaysen and Morris 1947). Gerstel and Place (1976) were the 
first to obtain a patent for the architecture of microneedle arrays, outlining a drug solution 
reservoir to a flow-through hollow microneedle. In 1998, a paper on the fabrication of 
microneedles used silicon-layered chromium for ‘coat and poke’ delivery of drugs (Henry et 
al. 1998). The first published fabrication of biodegradable microneedles used 
micromachining technology to mould polycaprolactone polymer into microneedles (Armani 
and Chang 2000; Park et al. 2003). At the moment, there is clearly an increasing interest in 
preparing biodegradable microneedles for a variety of applications. 
Preparation and treatment of normal skin surface before the application of a microneedle 
has not been recommended. Most literature suggests that pathogenic infections are not 
caused by using microneedles (Arora et al. 2008; Donnelly et al. 2009; Han et al. 2012). The 
removal of microneedles leaves indents on the skin and the main factors, such as 
microneedle length, number in an array and microneedle cross-sectional area, effect the 
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time for natural skin resealing (Gupta et al. 2011). For example, Kalluri and Banga (2011) 
have characterised the micro-conduit channels caused by microneedles and pore re-sealing. 
They show that skin pores close partially in approx. 12 h and completely in approx. 15 h.  
 A direct thumb application for biodegradable microneedles allow the drugs encapsulated 
inside the microneedles to diffuse into the viable epidermis of the skin as outlined 
schematically in Fig. 2a (Shakeel et al. 2011; Kim et al. 2012a). However in the case of 
lidocaine, if the drug is concentrated in the middle to lower portion of the microneedle than 
the tip, the permeation is expected to be in the stratum corneum (SC) layer of the skin to 
anaesthetise a superficial cut.  
 
 
 
As such, one needs to consider where the drug is loaded in the microneedles. Compared 
with glass and metal microneedles, biodegradable microneedles have no or little safety 
concern if they break and embed in the skin as a foreign body (Park et al. 2007a). Also, the 
manufacturing process and reproducibility of biodegradable microneedles are economical 
compared with conventional micro-machining manufacture (Donnelly et al. 2010). Fig. 2b is 
an image of sodium carboxymethyl cellulose-biodegradable microneedles encapsulated with 
the drug sulforhodamine B and Fig. 2c is an SEM plan view of PLGA microneedles (Jeong et 
al. 2008; Park et al. 2007a). 
 
 
 
 
 
Fabrication of biodegradable microneedles from substrate masters. 
Biodegradable microneedles have been fabricated by a variety of means. For example, 
silicon master substrate is adapted in MEMS applications and less time consuming, mass 
Fig. 2 a 
Fig. 2 b 
Fig. 2 c 
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producing techniques were researched via operations from the microelectronics industry, 
known as microelectronic mechanical systems (MEMS) for the fabrication of a master 
microneedle array prior to micromoulding (Fujita 1997; Walraven 2003; Trautmann et al. 
2005). SU-8, 1-methoxy-2-propyl acetate, (Microchem Corp, MSDS) is a negative 
photoresist material mixed with a Sulfonium salt photoinitiator for inducing the mechanism of 
cationic polymerisation in epoxy groups of SU-8 monomers under UV (Zhang et al. 2001; 
Qvortrup et al. 2011). It is photosensitive to UV light and a special mask diffraction grating is 
required to direct a particular wavelength onto the SU-8 (Ami et al. 2011). SU-8 does not 
always provide accurate structures and cases of bending brought by high residual stress 
were observed when photoresist and substrate posses incompatible thermal expansion 
coefficients. As such, the UV exposure time and wavelength range need close monitoring to 
prevent the distorting structure (Safavieh et al. 2010; Del Campo and Greiner 2007). 
Marasso et al. (2011) implemented double spin coating with two different viscosities of SU-8 
and observed good adhesion properties between copper substrate and SU-8 in-conjunction 
to an aspect ratio of 7:1 without additional steps such as wafer removal and seed layer 
introduction, extending production period over 24 h. Also, the viscosity and set thickness of 
the SU-8 photoresist are dependent on the amount of γ-butyrolactone solvent dissolved in 
producing the solution (Lorenz et al. 1997). 
A recent starting material for production of master templates was reported by Viero et al. 
(2012). They used reactive-ion etching (RIE) on silicon based master for the construction of 
microneedles. Chen et al. (2008) also outlined a fabrication process which used silicon oxide 
layers on silicon followed by a positive photoresist treatment for pattern transfer onto the 
silicon oxide layer via RIE and finally producing microneedle tips using an isotropic RIE 
process. Lhernould and Delchambre (2011) arrived at a design fabrication process of 
implementing laser ablation to create microchannels in polycarbonate material. Matteucci et 
al. (2009) adapted the micro-fabrication process known in German as lithographie, 
galvanoformung, abformung (lithography, electroplating and molding) by Hruby (2001) which 
produced microneedles by double-exposure, deep X-ray lithography (Kim et al. 2004) using 
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microcrystalline silicon wafers surfaced with Cr/Au bilayer as a template. Even though 
complicated multi-step processes and specialist resources are required in the production of 
a large quantity of master microneedles, the production of a single master is economical and 
time saving when considering the transferability in creating an inverse micromould for 
biodegradable microneedles (Kim et al. 2009; Kim et al. 2012b). 
 
Fabrication of biodegradable microneedles from moulds 
Biodegradable microneedles have been manufactured from micromoulds that are non-
interconnecting micro-well structures (Ryu et al. 2007). There is a lack of publications which 
outline the micro-moulding fabrication processes methodically. However, the manufacturing 
processes of casting and hot embossing are common for biodegradable microneedles, 
which are discussed briefly. In the casting process, a master template is fabricated to 
develop a mould template for a molten drug formula to fill the mould contours, solidify via 
favourable temperature and pressure conditions and finally removal of the mould from the 
solidified drug formula (Bariya et al. 2011). Poly-dimethyl-siloxane (PDMS) is an ideal 
material for replica moulding of microneedles because of its non-toxicity, elastic properties 
and low cost (Saliterman 2006; Lee and Lee 2008) and as such, it has been used in many 
studies. Laser ablation by focusing a CO2 laser was used to create conical shaped voids in 
PDMS material moulds for vacuum setting sodium carboxymethylcellulose and 
polyacrylamide solution into solid microneedles (Kim et al. 2009). In another study, a pre-
fabricated PDMS mould was used to vacuum set PLGA microneedles containing hydrogels 
(Kim et al. 2012b). PLGA is composed of D,L-polylactic acid (PLA) and polyglycoloic acid 
(PGA) monomers (Gabor et al. 1999; Danhier et al. 2012). As a biocompatible polymer, 
PLGA is used in biotechnology for the goal of preparing biodegradable microneedles and 
scaffolds in tissue engineering (Lee et al. 2004). It has been argued that PLGA with low 
molecular weights of less than 50 kDa and D,L-lactide/GA ratio of 50:50 are the most 
suitable for controlled drug release with respect to faster degradation rates (Fredenberg et al. 
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2011; Mundargi et al. 2008). PLGA in the context of merchandise is commercially and 
readily available from many chemical suppliers. 
 Stages in a typical casting process (Fig. 3a, Chu et al. 2010) start with a PDMS mould 
(step 1), pre-fabricated from a PDMS male master coated with gold, and the mould is filled 
with sulforhodamine B (step 2). The residual drug solution is pipette extracted half-way to be 
reused later (step 3) and the remaining drug solution in the mould crevice is dried by 
centrifugation. The PVA/PVP blend devoid of drug is casted into the mould by vacuum 
pressure (step 4), the combined polymer is air dried or low speed centrifuged in drying (step 
5) and adhesive backing is used to prise the formed polymer microneedles from the PDMS 
mould (step 6). Another biodegradable polymer system, poly-lactide-co-glycolide (PLGA) 
fabricated by Park et al. (2003) (Fig. 3b) commenced with SU-8 substrate (step 1) by using 
the same PLGA polymer as a sacrificial filler on SU-8 (step 2) followed by copper-coating 
deposition and acid etching to cover the SU-8 epoxy cylinders as a pattern (step 3) with 
subsequent reactive ion etching (RIE) to asymmetrically etch the tips of epoxy cylinders 
(step 4) and an inverse PDMS mould was created (step 5) with the prior master structure 
from RIE method before casting new PLGA microneedles as the final product (step 6) (Park 
et al. 2003). 
 
 
 
 
 A more economical method using a natural clay, chinese purple ceramic  mould was formed 
by hydraulic pressing a bed of steel sticks into the soft pliable clay before furnace heating, 
slow cooling followed by pouring a mixture of PVA, dextran and carboxymethylcellulose 
polymers into the mould then vacuum setting, freeze thawing and finally drying into 
microneedles (Yang et al. 2012).  
A less common fabrication technique known as hot embossing requires the application of 
heat above the glass transition temperature of the polymer product in contact with the mould 
Fig. 3 a  
Fig. 3 b 
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followed by force to emboss the mould pattern to the polymer product and then cooling 
below the glass transition temperature before separation of mould and polymer product 
(Bodhale et al. 2009). Poly-L-lactic acid (PLLA) is commercially and readily available from 
many chemical suppliers, similar to PLGA. PLLA microneedles were fabricated by a hot 
embossing technique through a multi-step process via a PDMS replication and then heating 
and pressuring the PDMS mould and PLLA grains followed by unmoulding at room 
temperature to obtain the microneedles (Han et al. 2009). A more efficient process was 
studied by Youn et al. (2008) by fabricating silicon moulds using focused ion beam and then 
pressing the silicon mould in poly-methyl-methacrylate (PMMA) polymer under applied 
temperatures above the glass transition temperature of PMMA and pressure followed by 
slow cooling  resulted in good reproducibility of replicated structures (Youn et al. 2008). Hot 
embossing appears only suitable for high temperature stable drugs in a biodegradable 
polymer vehicle as temperatures of over 100°C are required. 
As a substantial number of biodegradable microneedles are classed polymers, a 
supposedly third fabrication technique called investment moulding has been used suitably 
for hollow non-biodegradable polymers in which a drug solution flows through the hollow part 
of the microneedles into the skin (Lippmann 2007; Lippmann and Pisano 2006). Melt 
injection processes in investment moulding are suitable for thermoplastics because in 
adaptation of micromoulding, very high shear is required to allow for lower viscous melt and 
low resistant flow but heat generation can cause degradation of the drug formulation (Zhao 
et al. 2003). 
As mentioned earlier, currently there seems to be no lidocaine loaded biodegradable 
microneedle polymer systems published at present. Table 1 outlines the dissolvable or 
biodegradable materials as a vehicle for the drug and the method and conditions in 
manufacturing in-conjunction to significant dissolution or permeation results. 
 
 
 
Table 1 
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Possible biomaterials for controlled lidocaine release from microneedles 
Lidocaine requires controlled release microneedles that allow for initial fast release into skin 
but reaches the desired plateau levels in which finite dosage is achieved. Therefore, the 
microneedles have to dissolve or disintegrate in the tissue fluids of physiological conditions 
at that site near the laceration before medics can treat the area by cleaning and suturing. 
Drug molecules directly suspended in a well-mixed polymer microneedle matrix contribute to 
faster recorded time release than those encapsulated in microparticles followed by 
suspension in a second matrix vehicle as it is a two stage release mechanism with outer 
matrix dissolving first. For example, the time of drug release has been reported as 4 h when 
calcein was released from PLGA (85/15) obtained commercially in solid state via pre-
processed moulded microneedles compared with the same drug encapsulated in NaCMC 
followed by PLGA in which the result was reported as 4 days (Garland et al. 2011; Park et al. 
2006). The polymer and co-polymer monomeric ratios are influential in degradation for drug 
release. For example, single carbohydrate polymer poly-L-lactic acid (PLLA) with intrinsic 
viscosity value 2.38 was acquired commercially as a solid and processed into films and the 
result showed significantly slower degradation by hydrolysis in the release of lidocaine 
compared with PLGA (80:20) films which controlled released over 60% of lidocaine in forty 
days (Loo et al. 2010).  PLGA 50:50 microparticles loaded with lidocaine resulted in much 
faster controlled release of over 50% in 10 days (Klose et al. 2010). Lidocaine loaded PLGA 
would be highly suitable for relieving long duration symptoms of skin irritation and discomfort 
caused by illnesses such as postherpetic neuralgia, previously mentioned for commercially 
available lidoderm. PLLA’s starting monomers, L-lactic acid (LLA), can be derived by 
carbohydrate fermentation methods with lactic acid bacteria depending on the strain of 
lactobacillus (Garlotta 2001; Roy et al. 1982). The distinct synthetic step in the production of 
PLLA is the condensation polymerisation of LLA in which ester linkages between LLA 
monomers are formed and water is the by product (Mehta et al. 2005; Garlotta 2001). PLGA 
is synthesized by the mechanism of structural ring opening polymerisation of D,L-lactide and 
glycolide by catalysis from stannous 2-ethyl hexanoate in conjunction with a molecular 
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weight- regulating additive, triphenylsilanol with the overall objective of consistent chain 
length and reduction of side branch chains (Ouyang et al. 2011; Mazarro et al. 2009). 
Biodegradation in the context for polymers is the breakdown of a high molecular weight 
molecule into smaller components of low molecular weight molecules caused by enzymes 
from microorganisms and/or environmental catalysts (Luckachan and Pillai 2011; Wang et al. 
2003). Table 2 provides a summary of biodegradable polymer systems with respect of 
morphological properties and biodegradation measurements while physiological conditions 
according to plasma fluid are kept constant. The overall trend from Table 2 shows that the 
degradation is faster for PLLA blends than PLLA itself. Also, it seems that PLGA 50:50 is 
much faster degrading than PLGA 75:25. 
 
 
 
Tensile properties of biodegradable microneedles 
Dissolvable/biodegradable microneedles require quality testing to determine the maximum 
direct force required on the base unit before fracturing or crumbling occurs from the tip to the 
body of the microneedles. Such a test can be done using an axial load testing station which 
relies on gradually moving the microneedles into a block of metals (e.g. aluminium) until 
needle breakages are evident (Bariya et al. 2011). A measured section of the metal block 
contains a pre-determined thickness of skin attached by dual sticky tape and the other 
section of the block is connected to a compression cell containing microneedles and 
motorised actuator. The actuator provides a method for constant speed of microneedles 
insertion into the skin with the output measurement as force (Khanna et al. 2010). A number 
of components have been used to control tensile strength of dissolving microneedles as 
shown in Table 3. 
 
 
Conclusions 
Table 3 
Table 2 
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Although a number of lidocaine based transdermal products can be found in the market 
there is a large gap for lidocaine microneedle products, especially biodegradable 
microneedles. This implies that considerable amount of new research is required at the 
developmental and pre-clinical setting in order to achieve the desired controlled release of 
lidocaine into skin and maintain a steady drug concentration for a short duration of time for 
the purpose of superficial suturing of a cut. A biodegradable lidocaine microneedle system 
formulated from carboxymethylcellulose demonstrated the increase in pharmacokinetic 
permeation flux, thus highlighting further interest in research of other biodegradable 
materials as drug vehicles for lidocaine with the aim of achieving faster permeation kinetics 
in skin with the general idea of a minimal delayed therapeutic action. Also, the development 
of lidocaine microneedles may provide a scope for a cheaper product as compared with 
current EMLA formulations containing lidocaine in which a second local anaesthetic, 
prilocaine add to the material costs.  
The manufacturing of biodegradable microneedles via a casting process with usage of 
SU-8 or PDMS moulds is economical mainly because these moulds can be re-used 
numerous times in mass production of biodegradable microneedles. The mechanical 
penetration strengths are a highly important physical challenge seen in biodegradable 
microneedles. Not only is a sharp tip of microneedle necessity in cutting through skin but the 
casted dissolvable material requires adequate resistant to compression forces that mimic 
finger or thumb pressures. Dissolvable materials with soft solid or brittle physical properties 
require mucoadhesive co-polymer agents such as PVA or PVP in the mixture to provide for 
mechanical strength. 
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Table 1 Fabricated microneedles according to manufacture, dissolution and permeation of 
drug 
Microneedle 
materials 
Methods of  
ma n u f a c t u r e 
Condi t ions of   
ma n u f a c t u r e  
Results of drug 
permeation or 
dissolution of vehicle 
PLA, PLGA (50/50) 
and PEG unmixed 
initially (Park et al. 
2007b) 
 
 
Casting with PDMS 
(Park et al. 2007b; 
Xiangdong et al, 2009) 
SU-81 photoresist 
master (Natarajan et 
al. 2008), gold coating 
o f  5 0 0 Ǻ . 
Ultrasound pulses to 
weld polymer 
microparticles within 
mould to create porous 
structure (Park et al. 
2007b). Vacuum 
pressure and oven 
heating for microneedle 
static shaping (Park et 
al. 2007b) 
No publication found 
Silk fibroin from B. 
mori c ocoons2 (You 
et al. 2011)  
Epoxy microneedle 
master from X-ray 
lithography to produce 
female PDMS3 mould 
(You et al. 2011). 
Molten fibroin drug set 
into PDMS and mould 
removed (You et al. 
2011) 
Oven drying and 
vacuum pressure for 
shaping and solidifying 
microneedles (You et al. 
2011) 
No publication found. 
Poly (methyl vinyl 
ether co-maleic acid) 
(Garland et al. 2012) 
Blulase  laser cutting 
for fabricated silicone 
elastomer moulds 
using Aluminium 
template (Garland et 
40°C heat for curing 
mould and centrifugation 
at 3500 g for 15 min and 
microneedles dried for 
24 h under ambient 
In vitro studies with 
Neonatal procine skin 
reported 59%, 39% 
and 23% cumulative 
release of caffeine, 
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al. 2012) temperature (Garland et 
al. 2012) 
lidocaine and 
metronidazole 
respectively for 
combined concoction 
microneedles were 
tested (Garland et al. 
2012) 
20% (w/w) aqueous 
blends of co-polymer 
Gantrez® AN-139 
(Donnelly et al. 2011) 
Galvanometer 
controlled Excimer 
laser for variable 
height and 
interspacing of 
microneedle mould 
setup (Donnelly et al. 
2011) 
 
Blulase  laser cutting 
for fabricated silicone 
elastomer moulds 
using Aluminium 
template (Donnelly et 
al. 2011) 
40°C heat for curing 
mould and centrifugation 
at 3500 g for 15 min and 
microneedles dried for 
24 h under ambient 
temperature (Donnelly 
et al. 2011) 
83% of the drug, 
theophylline, contained 
in microneedles, 
permeated past the 
skin compared to 5.5% 
with patch delivery 
over a 24 h period 
(Donnelly et al. 2011) 
The percentage is out 
of total drug loaded.  
Trehalose/mannitol  
(50:50 w/w), 
trehalose dihydrate/ 
sucrose (75:25 w/w), 
trehalose/sucrose 
(75:25 w/w) and 
trehalose/sucrose 
(50:50 w/w) (Martin 
PDMS3 mould created 
from wet etched silicon 
male master (Martin et 
al. 2012) 
1 h vacuum pressure of 
(100 mbar) at room 
temperature conditions 
followed by 48 h 
dehydration without 
vacuum (Martin et al. 
2012)  
Sugar glass 
microneedles 
containing 2% (w/w) 
methylene blue 
powder showed 
complete dissolution 
between 10 to 20 min 
after insertion into full 
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et al. 2012)  thickness human skin 
(Martin et al. 2012) 
Maltose 
monohydrate (1 g/ml) 
in deionised water 
(Lee et al. 2011b) 
Stainless steel pillars 
and syringe pump to 
directly draw molten 
maltose into conical 
microneedles (Lee et 
al. 2011b) 
Axial drawing at 400 
μm/s for 1 s at 100 °C 
then 400 μm/s for 3 s at 
96 °C, cooling to 60 °C 
and separation from 
attached support pillars 
at 700 μm/s (Lee et al.  
2011b) 
Optical micrography 
showed complete 
dissolution of maltose 
microneedle 
containing 
sulforhodamine B in 
guinea pig skin after 
20 min (Lee et al.  
2011b) 
Maltose (analytical 
grade) in water (Kolli 
and Banga 2008)  
Pre-fabricated inverse 
moulds formed by 
etching process 
(Texmac Inc) 
Direct pouring of molten 
maltose at 95 °C into 
mould within one min 
and gradual cooling to 
55 °C to prise out the 
mould from shaped 
microneedles (Kolli and 
Banga 2008; Miyano et 
al. 2005) 
Nicardipine- 
hydrochloride loaded 
maltose microneedles 
recorded a mean flux 
of 7.05 μg/ml/h 
compared with control 
value of 1.72 μg/ml/h 
(Kolli and Banga 2008) 
1 SU-8 is a high viscosity, negative based photo resist structure for moulding applications. 
2 B. mori cacoons are natural silk cocoon fibrons spun by the silkworm, Bombyx mori. 
3 PDMS is a silicone based inert polymer material, polydimethylsiloxane.   
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Table 2 Polymer biodegradation and morphology according to physiological plasma fluid 
conditions. 
Polymer Morphological properties Degradation studies in physiological1 
conditions 
Poly–Ɛ-caprolactone (PCL) Injection moulded matrix, 
films and sheets via 
temperature settings (Wahit 
et al. 2012) 
General long term degradation from 
weeks to months (Dash and 
Konkimalla 2012). In vivo 
degradation cannot occur readily 
due to unavailability of desired 
enzymes and surface erosion 
caused by hydrolysis is the primary 
mechanism and the main reason for 
slow degradation of PCL (Ginde and 
Gupta 1987; Woodruff and 
Hutmaker 2010)  
PLLA 200 micron and 20 micron 
films (Mattioli et al. 2012)  
5% weight loss by hydrolytic 
degradation after 49 days (Mattioli et 
al. 2012) 
Mixed mPEG5000–PSA2 
and mPEG2000–PLLA3 
(Lai et al. 2012) 
Spherical micelles with 
hydrophobic matrix and 
hydrophilic exterior layer (Lai 
et al. 2012). 
Degradation measured from 
calculation percentage release of 
curcumin in PBS4. Burst release of 
curcumin near to 40%. Maximum 
75% approximate release of 
curcumin on day 15 (Lai et al. 2012).  
P (LLA-co-ƐCL)5 and 
P(LLA-b-ƐCL)6 (Choi et al. 
2002). 
 
P(LLA-co-ƐCL) (90/10) 
(Kalpan et al. 2007) 
240 micron thick films (Choi 
et al. 2002) 
 
 
Smooth surface 
Microspheres (Kalpan et al. 
No degradation studies carried out 
at physiological conditions so far. 
 
 
60% decrease by hydrolytic 
degradation in molecular weight 
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PHCL-g-PLLA7 (Dai et al. 
2009) 
2007) 
 
Comb graft polymer films of 
110 -120 microns (Dai et al. 
2009) 
after 112 days (Kalpan et al. 2007) 
 
55% weight loss after 70 days (Dai 
et al. 2009)  
PLGA 
 
 
 
5600 micron diameter 
Sirolimus8 loaded films (Ro  
et al. 2012) 
25% weight loss after 13 days for 
Sirolimus loaded PLGA 50:50 (Ro et 
al. 2012). 
 
22% mass loss after 55 days for 
Sirolimus loaded PLGA 75/25 (Ro et 
al. 2012) 
1   Conditions refer to a plasma fluid of pH 7 and temperature of 37 °C. 
2 Methoxy poly(ethylene glycol) (mPEG), 5000 Daltons, Poly(sebacic anhydride) (PSA). 
3 Methoxy poly(ethylene glycol) (mPEG), 2000 Daltons. Poly-L-lactide (PLLA). 
4 Phosphate buffer solution, pH 7.4.  
5   P(LLA-b-_CL) is a diblock co-polymer with MW 15200 
6   P(LLA-co-_CL) is a random polymer with MW 51000  
7 PHCL-g-PLLA poly(4-hydroxyl-e-caprolactone-co-e-caprolactone)-g-poly(L-lactide) 
8 Sirolimus is an immunosuppressant drug 
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Table 3 Mechanical force properties of microneedle materials and force test results of the 
microneedle systems 
Microneedle system Component with external 
force tolerance 
Results of force tests  
Polylactic acid (PLA) (Wang 
and Jeng. 2009) 
Injection grade PLA (Wang 
and Jeng 2009) 
73.11% impact on structural due 
to melt temperature variable 
(Wang and Jeng 2009) 
NIPAAm1 based hydrogel 
loaded into Poly lactic-co-
glycolic acid (PLGA) (Kim et al. 
2012) 
Mainly PLGA (Kim et al. 
2012) 
PLGA microneedles with 18% v/v 
hydrogel deformed less than the 
31% v/v hydrogel ones (Kim et al. 
2012) 
Sugar glass disaccharide 
mixture of two sugar 
components except xylitol 
(Martin et al. 2012) 
Similar molecular weight of 
two specific disaccharides 
that formed solid sugar 
(Martin et al. 2012) 
Qualitative skin penetration tests 
showed most microneedles 
penetrated skin and complete 
dissolution in skin after 10 min 
(Martin et al. 2012) 
Polyvinylpyrrolidone (PVP), 
PLGA, PVA (Ke et al. 2012) 
PVP (10000 MW) (Ke et al. 
2012) 
Microneedles fabricated with 600 
mg/ml and 1000 mg/ml PVP were 
robust as confirmed from SEM 
images after insertion. The latter 
PVP concentration showed no 
geometric change (Ke et al. 2012) 
PVP, PVP-MAA2 poly(vinyl 
pyrrolidone-co-methacrylic 
acid (Sullivan et al. 2008) 
PVP (8970 MW), MAA 
(Sullivan et al. 2008) 
Displacement force tests proved 
that 1% MAA in PVP-MAA 
contributed to nearly double the 
strength of PVP alone (Sullivan et 
al. 2008) 
PVA/PVP blends (Chu et al. 
2010) 
PVA (2000 MW) (Chu et al. 
2010) 
Qualitative skin penetration tests 
showed 80% of microneedle tips 
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of length 450 μm dissolved in 
porcine skin after 2 min with bright 
field microscopy (Chu et al. 2010) 
1   N-isopropylacrylamide (NIPAAm)  
2  Poly (vinyl pyrrolidone-co-methacrylic) acid 
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Fig. 2 c Scanning electron microscope image of conical PLGA microneedles (Park et al. 
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